On the evening of December 3, the announcements of these listed pharmaceutical companies were interesting

On the evening of December 3, a number of listed pharmaceutical companies issued announcements, including good news such as product inclusion in the medical insurance catalog, product approval, product review, and events such as investment and financing, increase and decrease in holdings.
Click here for the important announcements, let’s take a look~ 【Product Events】 Hengrui Pharmaceuticals: 9 products are included in the National Medical Insurance Catalog
.
Among them, Hytrapapax ethanolamine tablets, fluzoparib capsules, remazolam tosylate for injection, and azisartan tablets for injection were included for the first time; new indications for apatinib mesylate tablets were included; maleic acid Pirrotinib tablets and thiopefilgrastim injection were successfully negotiated for contract renewal; glycopyrrolate injection was directly included; bevacizumab injection was adjusted from the "part of the negotiation period of the agreement" to the regular national medical insurance list
.
Aidi Pharmaceuticals: Ainovirin tablets are included in the national medical insurance catalog.
Aidi Pharmaceuticals announced in the evening that the company's anti-AIDS national class 1 new drug Ainovirine tablets was included in the national medical insurance catalog for the first time through medical insurance negotiations
.
Fu Medicine: The two subsidiaries of the company were included in the National Medical Insurance Catalog, Renfu Medicine announced that the company's 80%-owned subsidiary Yichang Renfu Pharmaceutical's products for injection remazolam besylate and midazolam oral solution were successfully negotiated and included National Medical Insurance Directory
.
Remazolam besylate for injection is suitable for colonoscopy sedation; midazolam oral solution is used for sedation/anti-anxiety/amnesia before children's diagnosis or therapeutic operation and during operation; or for children before operation Calm/anti-anxiety/amnesia
.
Hisun Pharmaceutical: Haibo Maibu Tablets have newly entered the National Medical Insurance Catalog Hisun Pharmaceutical announced in the evening that the company's Haibo Maibu Tablets have newly entered the "Part of Negotiations during the Agreement Period" of the "2021 Medical Insurance Catalog"
.
This product is the first small molecule innovative drug independently developed by the company, and is the first in China and the second oral intestinal cholesterol absorption inhibitor in the world
.
Iris: Vometinib mesylate tablets are newly included in the National Medical Insurance List.
Iris announced that the company's self-developed Class 1 new drug, Vometinib Mesylate, was included in the National Medical Insurance List for the first time
.
Vometinib mesylate is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), used for the treatment of advanced non-small cell lung cancer
.
Haichen Pharmaceuticals: Landiolol Hydrochloride for Injection is included in the National Medical Insurance Catalog Haichen Pharmaceuticals announced that the company's landiolol hydrochloride for injections was transferred to the National Medical Insurance Catalog for 2021
.
The drug is an important cardiovascular therapy drug with a wide range of effects
.
Huiyu Pharmaceuticals: Bendamustine Hydrochloride for Injection is included in the National Medical Insurance Catalogue Huiyu Pharmaceuticals announced that the company's main product, Bendamustine Hydrochloride for Injection, has been newly added and directly included in the National Medical Insurance Catalogue
.
This product is suitable for indolent B-cell non-Hodgkin lymphoma (NHL) that progresses during or after treatment with rituximab or rituximab-containing regimens
.
Zejing Pharmaceuticals: Medonafenib tablets are included in the National Medical Insurance Drug List Zejing Pharmaceuticals announced that the company's self-developed Class 1 new drug Donafinil Toluenesulfonate Tablets passed the national medical insurance negotiations and was included in the National Medical Insurance Drug List
.
This product is an oral multi-target, multi-kinase inhibitor small molecule anti-tumor drug independently developed by the company, and belongs to a class 1 new drug
.
Salubris: Alicante medoxomil tablets renew the national medical insurance catalog Salubris announcement, the company's innovative drug Alli medoxomil tablets negotiated contract, into the national health insurance directory B range
.
It is understood that this product is mainly used for the treatment of mild to moderate essential hypertension
.
Tibet Pharmaceuticals: Xinhuosu renewed its contract to be included in the National Medical Insurance Drug List.
Tibet Pharmaceuticals announced that the company’s wholly-owned subsidiary, Chengdu Nuodikang’s recombinant human brain natriuretic peptide for injection, was successfully renewed and was included in the National Medical Insurance List B Range
.
As a genetically engineered drug for the treatment of acute heart failure, Xinhuosu can quickly improve the symptoms and signs of heart failure in patients with heart failure, and improve the quality of life of patients
.
Zhejiang Pharmaceuticals: Two new products or renewal of contracts entered the National Medical Insurance Catalogue Zhejiang Pharmaceutical Announcement, the company's nanofloxacin malate sodium chloride injection and nanofloxacin malate capsules were added or renewed to enter the national medical insurance Directory
.
Chipper Bio: Cidabenamide continued to be discussed and included in the National Medical Insurance Catalogue
.
Chidamide tablets are anti-tumor drugs and immunomodulators-other anti-tumor drugs
.
Fosun Pharma: Bevacizumab injection was approved for listing and registration.
Fosun Pharma announced that the bevacizumab injection (ie, recombinant anti-VEGF humanized monoclonal antibody injection) of the holding subsidiary Hanlius Pharmaceuticals was used for The marketing registration application for the treatment of metastatic colorectal cancer and advanced, metastatic or recurrent non-small cell lung cancer has been approved by the State Food and Drug Administration
.
The company said that the new drug has been approved for listing and registration, which will enrich the group's product line
.
Baiyunshan: Amoxicillin Capsules passed the generic drug consistency evaluation.
Baiyunshan announced that the branch company Baiyunshan Pharmaceutical General Factory received the "Drug Supplementary Application Approval Notice" issued by the State Food and Drug Administration.
Amoxicillin capsules have passed the quality of generic drugs And evaluation of consistency of efficacy
.
According to data from Minai.
com, the sales of amoxicillin capsules in public hospitals and urban retail pharmacies in China in 2020 will be 270 million yuan and 1.
05 billion yuan respectively
.
Cucurbita: Omeprazole Sodium for Injection has passed the Generic Drug Consistency Evaluation Cucurbita Announcement.
The company has recently received the "Drug Supplementary Application Approval Notice" on "Omeprazole Sodium for Injection" approved and issued by the State Food and Drug Administration.
, The drug passed the evaluation of the consistency of the quality and efficacy of generic drugs
.
[Investment and Financing] Northland: plans to raise 300 million yuan to invest in drug research and development, etc.
Northland has announced that it plans to issue no more than 32 million shares to specific targets through bidding (accounting for 12.
44% of the current total share capital) , The amount of raised funds does not exceed 300 million yuan, which will be used for drug research and development projects (82.
17 million yuan), bioengineering new drug industrialization projects (18.
289 million yuan) and supplementary working capital (28.
541 million yuan)
.
It is worth mentioning that this is the first company to apply for a refinancing project since the opening of the Beijing Stock Exchange
.
[Increase and decrease of holdings] Jinyu Medical: Shareholders calculate and reduce the company’s holdings by no more than 3.
8% Jinyu Medical Announcement, Guangzhou Xinyiyu Investment Management Partnership (Limited Partnership), Guangzhou Shengboyu Investment Management Partnership (Limited) Partnership) and Guangzhou Ruizhi Investment Management Partnership (Limited Partnership) intend to reduce their holdings of the company’s shares by not more than 17.
6923 million shares through block transactions, accounting for 3.
8% of the company’s total share capital
.
The above-mentioned shareholders are persons acting in concert, and their executive partners are all controlling shareholders of the company
.
Zhenghai Bio: The actual controller and its concerted parties will reduce their holdings by no more than 4% of the shares.
The company announced that the company's controlling shareholder, actual controller Mi Bohai and its concerted person, Jiaxing Zhenghai plans to use centralized bidding transactions or block transactions , The total reduction of the company’s shares shall not exceed 4.
8 million shares, that is, not more than 4% of the company’s total share capital
.